ClinicalTrials.gg

Program

belantamab mafodotin

Also written as “Belantamab mafodotin”, “Belantamab Mafodotin” and “GSK2857916”.

Its studies are mostly in Multiple Myeloma · Amyloidosis, led by GlaxoSmithKline.

Furthest: phase 3, since Nov 11, 201925 company-led studies, 18 open or runningNext primary completion: Aug 3, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline2518 open or runningphase 3since Nov 11, 2019Feb 13, 2014Aug 3, 2028phase 2 · NCT05714839

Also a collaborator on its studies: Merck.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 6 studies since Feb 13, 2014.

  1. May 19, 20202 phase 1 studies in Multiple MyelomaNCT04398745, NCT04398680
  2. Jul 21, 2020Phase 3 study in Multiple MyelomaNCT04484623 · 302 enrolled · United States, Australia, Brazil and more
  3. Sep 8, 2020Phase 3 study in Multiple MyelomaNCT04549363 · 16 enrolled · United States
  4. Sep 22, 2021Phase 2 study in Multiple MyelomaNCT05064358 · 177 enrolled · United States, Argentina, Australia and more
  5. Jan 27, 2023Phase 2 study in Multiple MyelomaNCT05714839 · 123 planned · United States, Argentina, Australia and more
  6. Oct 22, 2024Phase 2 study in Multiple MyelomaNCT06655818 · 4 enrolled · France, Korea, Republic of
  7. Nov 6, 2024Phase 3 study in Multiple MyelomaNCT06679101 · 520 planned · United States, Argentina, Australia and more
  8. Mar 6, 20252 phase 3 studies in Multiple MyelomaNCT06868667, NCT06868654
  9. Apr 25, 2025Phase 3 study in Multiple MyelomaNCT06956170 · 21 enrolled · Japan
  10. Jul 22, 2025Phase 2 study in Multiple MyelomaNCT07084896 · 106 enrolled · United States, Australia, Canada and more
  11. Aug 25, 20252 phase 2 studies in Multiple MyelomaNCT07150104, NCT07150091
  12. Oct 13, 20253 phase 2 studiesNCT07217184, NCT07217119, NCT07224672
  13. May 20, 2026Phase 1 study in Multiple MyelomaNCT07609706 · 20 planned
  14. May 21, 2026Phase 2 study in Multiple MyelomaNCT07614360 · 150 planned

Ahead

  1. Aug 3, 2028Primary completion: phase 2 study in Multiple MyelomaNCT05714839
  2. Feb 28, 2029Primary completion: phase 2 study in Multiple MyelomaNCT07614360
  3. Apr 28, 2031Primary completion: phase 3 study in Multiple MyelomaNCT06679101
  4. Aug 22, 2031Primary completion: phase 1 study in Multiple MyelomaNCT07609706

TargetBeta

TNFRSF17 →read by rule
“An antibody-drug conjugate (ADC) consisting of belantamab, an afucosylated, humanized monoclonal antibody, directed against the B-cell maturation antigen (BCMA), ”NCIt, by rule
“Tumor necrosis factor receptor superfamily member 17 binding agent”ChEMBL 37, by rule

Other programs on TNFRSF17

ProgramCompanyFurthest phaseStudies
elranatamabrulePfizerphase 415
linvoseltamabruleRegeneron Pharmaceuticalsphase 413
teclistamabruleJohnson & Johnsonphase 411
Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012FAstraZenecaphase 312
etentamigAbbViephase 311
ramantamigJohnson & Johnsonphase 37
anitocabtagene autoleucelruleGilead Sciencesphase 36
equecabtagene autoleucelrulenanjing-iaso-biotechnology-co-ltdphase 35
Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934Sino Biopharmaceuticalphase 34
GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003ruleInnovent Biologicsphase 34
Evarucabgene Autoleucelrulenexcella-incphase 32
Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytesrulecartesian-therapeuticsphase 26

Studies

All 25 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07614360Multiple Myeloma2Not yet recruitingFeb 28, 2029150
NCT07609706Multiple Myeloma1Not yet recruitingAug 22, 203120
NCT07224672Amyloidosis · United States, Australia, United Kingdom2RecruitingJan 12, 203360
NCT07217184Multiple Myeloma · United States, Australia, Brazil and more2Active, not recruitingApr 17, 202530
NCT07217119Multiple Myeloma · United States, Australia, Canada and more2Active, not recruitingApr 17, 202525
NCT07150104Multiple Myeloma · Brazil, Canada, France and more2Active, not recruitingApr 17, 202514
NCT07150091Multiple Myeloma · United States, Brazil, Canada and more2Active, not recruitingApr 17, 202520
NCT07084896Multiple Myeloma · United States, Australia, Canada and more2Active, not recruitingApr 17, 2025106
NCT06956170Multiple Myeloma · Japan3Active, not recruitingMay 27, 202421
NCT06868667Multiple Myeloma · Japan3Active, not recruitingApr 3, 202424
NCT06868654Multiple Myeloma · China3Active, not recruitingApr 3, 202472
NCT06679101Multiple Myeloma · United States, Argentina, Australia and more3RecruitingApr 28, 2031520
NCT06655818Multiple Myeloma · France, Korea, Republic of2TerminatedFeb 14, 20244
NCT05714839Multiple Myeloma · United States, Argentina, Australia and more2RecruitingAug 3, 2028123
NCT05064358Multiple Myeloma · United States, Argentina, Australia and more2CompletedAug 19, 2024177
NCT04549363Multiple Myeloma · United States3TerminatedNov 21, 202216
NCT04484623Multiple Myeloma · United States, Australia, Brazil and more3Active, not recruitingJan 29, 2024302
NCT04398745Multiple Myeloma · Greece, South Korea1Active, not recruitingApr 21, 202536
NCT04398680Multiple Myeloma · United States, Greece, South Korea1WithdrawnNov 4, 20250
NCT04246047Multiple Myeloma · United States, Australia, Belgium and more3Active, not recruitingOct 2, 2023494
NCT04177823Multiple Myeloma · China1CompletedDec 30, 20216
NCT04162210Multiple Myeloma · United States, Australia, Belgium and more3Active, not recruitingSep 12, 2022325
NCT04091126Multiple Myeloma · United States, Australia, Canada and more1Active, not recruitingJun 2, 2025118
NCT03848845Multiple Myeloma · United States, Canada, Germany and more2CompletedOct 18, 202141
NCT02064387Multiple Myeloma · United States, Canada, United Kingdom1CompletedAug 31, 201879

How it is read

Names in the registry

  • “Belantamab mafodotin”, 22 entries
  • “Belantamab Mafodotin”, 1 entry
  • “belantamab mafodotin”, 1 entry
  • “GSK2857916”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.